NYSE American - Delayed Quote USD

Actinium Pharmaceuticals, Inc. (ATNM)

Compare
1.2900 +0.1700 (+15.18%)
At close: December 20 at 4:00:00 PM EST
1.2800 -0.01 (-0.78%)
After hours: December 20 at 7:59:18 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ATNM

Recent News: ATNM

View More
Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024
PR Newswire last month

Actinium: Q3 Earnings Snapshot
Associated Press Finance last month
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
PR Newswire last month
All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy

All You Need to Know About Actinium (ATNM) Rating Upgrade to Strong Buy
Zacks 2 months ago
Actinium Pharmaceuticals reports data from Phase III trial of AML treatment

Actinium Pharmaceuticals reports data from Phase III trial of AML treatment
Clinical Trials Arena 2 months ago
Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology

Actinium Pharmaceuticals Announces Publication of Results from the Phase 3 SIERRA Trial of Iomab-B in the Journal of Clinical Oncology
PR Newswire 3 months ago

Actinium: Q2 Earnings Snapshot
Associated Press Finance 4 months ago

Sector Update: Health Care Stocks Fall in Afternoon Trading
PREMIUM
MT Newswires 4 months ago
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.

Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
PR Newswire 4 months ago
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications

Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
PR Newswire 4 months ago
Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University

Actinium Announces FDA Clearance of Iomab-ACT Targeted Conditioning IND Application for Sickle Cell Disease Patients Undergoing Bone Marrow Transplant in Collaboration with Columbia University
PR Newswire 4 months ago
View More

Related Tickers

ACET Adicet Bio, Inc.
0.9100
+5.78%
 
SLS SELLAS Life Sciences Group, Inc.
0.8880
-1.11%
 
ENTX Entera Bio Ltd.
2.1000
-3.23%
 
AFMD Affimed N.V.
1.1900
+0.85%
 
AGEN Agenus Inc.
2.8300
+2.54%
 
MREO Mereo BioPharma Group plc
3.3500
+1.82%
 
ALLK Allakos Inc.
1.2000
-6.98%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
1.3400
-10.67%
 
AXSM Axsome Therapeutics, Inc.
90.73
+1.10%
 
ATYR aTyr Pharma, Inc.
3.3500
+6.35%